From the Journals
Feature

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

Share

  • 1

    GLP-1RAs do not significantly increase overall cancer risk.

  • 2

    Study involved 48 randomized trials with 94,245 participants.

  • 3

    Moderate-certainty evidence for little or no effect on thyroid and pancreatic cancers.

  • 4

    Observational studies show conflicting results regarding obesity-related cancers.

  • 5

    Longer follow-up studies needed to assess long-term cancer risk.

Original Source(s)

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

  • by Doug Brunk

  • December 11, 2025

  • 4 min

Related Content

Liver Supplements: Big Sales, Limited Evidence

Researchers evaluate how popular liver cleanse products are formulated and promoted in the US online marketplace.

Gut Bacteria Linked to Insulin Resistance

Study highlights how 'Proteobacteria and bile acids in the gut negatively impact insulin sensitivity,' offering potential therapeutic targets across the microbiome-gut-adipose-liver axis.

Juice Cleanses May Alter Oral Microbiota

Popular juice-only diets may negatively impact oral and gut microbiomes.